BVF Inc. IL purchased a new stake in Erytech Pharma SA (NASDAQ:ERYP) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 625,000 shares of the company’s stock, valued at approximately $13,763,000. Erytech Pharma accounts for about 1.7% of BVF Inc. IL’s investment portfolio, making the stock its 19th biggest holding. BVF Inc. IL owned approximately 3.65% of Erytech Pharma as of its most recent SEC filing.
Separately, Sphera Funds Management LTD. bought a new position in Erytech Pharma during the fourth quarter worth $2,642,000. 26.91% of the stock is currently owned by institutional investors.
ERYP traded down $0.75 during trading on Monday, reaching $20.25. 203 shares of the company’s stock were exchanged, compared to its average volume of 1,445. Erytech Pharma SA has a fifty-two week low of $17.50 and a fifty-two week high of $30.56. The company has a market capitalization of $376.68 and a P/E ratio of -6.91.
Separately, Cowen started coverage on shares of Erytech Pharma in a research report on Tuesday, December 5th. They set an “outperform” rating on the stock.
WARNING: “BVF Inc. IL Takes Position in Erytech Pharma SA (ERYP)” was reported by Enterprise Leader and is the property of of Enterprise Leader. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://theenterpriseleader.com/2018/04/02/bvf-inc-il-invests-13-76-million-in-erytech-pharma-sa-eryp-stock.html.
Erytech Pharma Profile
Erytech Pharma SA, also known as ERYTECH Pharma, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The Company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells.
Receive News & Ratings for Erytech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erytech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.